AbbVie Contract Manufacturing has two manufacturing sites in Ireland, drawing on the strength of the local biopharmaceutical industry and scientific expertise. Both state-of-the-art facilities meet the ongoing needs of CMO clients in Ireland and beyond. 


AbbVie's Sligo facility is situated in northwest Ireland, approximately 130 miles from Dublin. It is one of the newest plants in AbbVie's portfolio, having begun operations in 2003 and recent expansion in 2014-2015. Our highly qualified team specializes in potent API and drug product development at this facility.  The team partners with companies looking for services that range from small-scale process development through to bulk commercial manufacturing.


AbbVie’s 110,000 ft2 Sligo location houses a state-of-the-art high containment facility and dedicated quality control labs. It is optimized for a wide range of potent pharmaceuticals, along with new product introduction (NPI) and development, along with regulatory experts on hand to help guide the process.

The Sligo facility is a dedicated cGMP plant for potent active pharmaceutical ingredients and potent drug products, and is IMB, EU and FDA approved for both large-scale commercial manufacture and clinical trial supplies. It is capable of handling the highest classifications of potent compounds – with containment levels up to OEB 5 (OEL <1 μg/m3), among the highest for pharmaceutical manufacturers in Ireland and globally.

AbbVie’s Sligo contract manufacturing expertise:

  • Potent
  • Tablet Coating
  • Massing Granulation (High Shear)
  • Massing Granulation (Single Pot)
  • Compressing Granulation (Roller Compactor)
  • Capsules
  • Direct Compression (Dry Blend)

AbbVie's has a network of manufacturing facilities around the world to support your project and project needs.  See AbbVie's other locations for additional manufacturing site information and technical expertise.  


AbbVie's Cork facility is situated in the south of Ireland, approximately 165 miles from Dublin. Founded in 2001, this 13 acre Irish drug contract manufacturing site houses a highly automated drug product manufacturing plant along with pilot scale production to support clinical drug production needs.   Our facility has an impressive track record of timely and cost efficient technical transfers. 


As a complement to our wider contract manufacturing capabilities around the world, our expertise in Cork includes tablets, mini-tablets and capsule formulations. The Cork facility is accredited by regulatory bodies, including the FDA and Irish Medicines Board (IMB) and it is licensed to distribute to the United States, Canada, Europe and much of the rest of the world.

This facility features a new product introduction launch site, equipped with  innovative technologies for the development of pipeline products.

AbbVie’s Cork contract manufacturing expertise:

  • Tablet Coating
  • Spray Coating (Glatt)
  • Massing Granulation (High Shear)
  • Massing Granulation (Low Shear)
  • Spray Granulation (Fluid Bed)
  • Bi-Layer Tablets
  • Drying Granulation (Fluid Bed)
  • Capsules
  • Particle Coating
  • Direct Compression (Dry Blend)
  • Micro-tablets

To discuss how these technologies can benefit your drug development program, contact AbbVie today.


AbbVie maintains a range of regional and global regulatory standards to meet guidelines enforced in your country of origin, and those of your intended markets. The Cork facility has earned certification for ISO 14001, ISO 18001, and ISO 50001 and meets FDA, ICH and EU requirements.